Table 1.
Description of study cohort
| Parameter | SSc–no CKD (n = 40) | SSc–CKD (n = 39) | History of SRC (n = 14) | CKD (n = 11) | Control (n = 12) |
|---|---|---|---|---|---|
| Age, years | 57 (2.1) | 63 (1.7) | – | 58 (5.1) | 34 (2.4) |
| eGFR, ml/min/1.73 m2 | 80 (1.5) | 45 (2.3) | – | 49 (7.7) | 87 (1.3) |
| dcSSc, n (%) | 10 (25) | 20 (51) | – | – | – |
| lcSSc, n (%) | 30 (75) | 19 (49) | – | – | – |
| ACA, n (%) | 13 (33) | 12 (30) | 0 | – | – |
| ATA (Scl-70), n (%) | 8 (20) | 2 (5) | 1 | – | – |
| ARA (RNApol), n (%) | 6 (15) | 12 (30) | 7 | – | – |
| AFA (U3RNP), n (%) | 0 | 3 (8) | 2 | – | – |
| Other ANA, n (%) | 13 (33) | 11 (27) | 4 | – | – |
Data are shown as the mean (s.e.m.) or number (percentage within study subgroup).
eGFR: estimated glomerular filtration rate; RNApol: anti-RNA polymerase antibody; SRC: scleroderma renal crisis; U3RNP: anti-fibrillarin autoantibody; ATA: anti-topoisomerase.